Recursion Pharmaceuticals (RXRX) Earnings Date, Estimates & Call Transcripts → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free RXRX Stock Alerts $9.74 +0.32 (+3.40%) (As of 01:04 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateAug. 13EstimatedActual EPS (May. 9) -$0.39 Beat By $0.04 Consensus EPS (May. 9) -$0.43 Read Call TranscriptListen to Call Get Recursion Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for RXRX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueRXRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RXRX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchWhat President Biden's new law means for investorsWhat's Got Musk, Bezos, and Gates So Excited? Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it.This expert just went public with all the details, including which stocks to jump on immediately. Recursion Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.41)($0.33)($0.37)Q2 20242($0.41)($0.33)($0.37)Q3 20242($0.41)($0.35)($0.38)Q4 20242($0.83)($0.40)($0.62)FY 20248($2.06)($1.41)($1.74)RXRX Earnings Date and InformationRecursion Pharmaceuticals last announced its earnings results on May 9th, 2024. The reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.04. The business had revenue of $13.80 million for the quarter, compared to analysts' expectations of $11.10 million. Its revenue for the quarter was up 14.0% compared to the same quarter last year. Recursion Pharmaceuticals has generated ($1.60) earnings per share over the last year (($1.60) diluted earnings per share). Earnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($1.47) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off prior year's report dates.Read More Recursion Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/13/2024Estimated)------- 5/9/2024Q1 2024($0.43)($0.39)+$0.04($0.39)$11.10 million$13.80 million 2/27/2024Q4 2023($0.46)($0.40)+$0.06($0.40)$12.37 million$10.89 million11/9/2023Q3 2023($0.38)($0.43)($0.05)($0.43)$12.20 million$10.53 million8/8/2023Q2 2023($0.38)($0.38)-($0.38)$10.43 million$11.02 million5/8/2023Q1 2023($0.35)($0.34)+$0.01($0.34)$15.93 million$12.13 million2/27/2023Q4 2022($0.15)($0.31)($0.16)($0.31)$66.68 million$13.68 million Get the Latest News and Ratings for RXRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/8/2022Q3 2022($0.36)($0.35)+$0.01($0.35)$6.43 million$13.16 million8/9/2022Q2 2022($0.35)($0.38)($0.03)($0.38)$5.60 million$7.67 million5/10/2022Q1 2022$0.51($0.33)($0.84)($0.33)$152.90 million$5.33 million3/23/2022Q4 2021($0.30)($0.38)($0.08)($0.38)$7.62 million$2.53 million11/10/2021Q3 2021($0.28)($0.28)-($0.28)$2.62 million$2.53 million8/12/2021Q2 2021($0.23)($0.31)($0.08)($0.31)$2.65 million$2.55 million Recursion Pharmaceuticals Earnings - Frequently Asked Questions When is Recursion Pharmaceuticals's earnings date? Recursion Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off last year's report dates. Learn more on RXRX's earnings history. Did Recursion Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) reported ($0.39) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.43) by $0.04. Learn more on analysts' earnings estimate vs. RXRX's actual earnings. How can I listen to Recursion Pharmaceuticals's earnings conference call? The conference call for Recursion Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Recursion Pharmaceuticals's conference call transcript? The conference call transcript for Recursion Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Recursion Pharmaceuticals generate each year? Recursion Pharmaceuticals (NASDAQ:RXRX) has a recorded annual revenue of $44.58 million. How much profit does Recursion Pharmaceuticals generate each year? Recursion Pharmaceuticals (NASDAQ:RXRX) has a recorded net income of -$328.07 million. RXRX has generated -$1.60 earnings per share over the last four quarters. What is Recursion Pharmaceuticals's EPS forecast for next year? Recursion Pharmaceuticals's earnings are expected to grow from ($1.60) per share to ($1.47) per share in the next year. More Earnings Resources from MarketBeat Related Companies: VCEL Earnings Date PTCT Earnings Date APGE Earnings Date KYMR Earnings Date ADMA Earnings Date ACLX Earnings Date BEAM Earnings Date TWST Earnings Date IMCR Earnings Date SANA Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Baidu Stock Earnings Prove Ray Dalio Right about China?JD’s Earnings Could Mean Chinese Stocks Making a ComebackHome Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-Turn This page (NASDAQ:RXRX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.